Search

Your search keyword '"Foroud, Tatiana"' showing total 3,105 results

Search Constraints

Start Over You searched for: Author "Foroud, Tatiana" Remove constraint Author: "Foroud, Tatiana"
3,105 results on '"Foroud, Tatiana"'

Search Results

51. Circular-SWAT for deep learning based diagnostic classification of Alzheimer's disease: application to metabolome data

52. Identification of genetic risk loci and causal insights associated with Parkinson's disease in African and African admixed populations: a genome-wide association study

53. Plasma Total-Tau and Neurofilament Light Chain as Diagnostic Biomarkers of Alzheimer’s Disease Dementia and Mild Cognitive Impairment in Adults with Down Syndrome

54. Brain volumetric deficits in MAPT mutation carriers: a multisite study

55. A large-scale genome-wide association study meta-analysis of cannabis use disorder.

56. Studying the natural history of frontotemporal lobar degeneration (FTLD): The ARTFL LEFFTDS longitudinal FTLD (ALLFTD) protocol

57. Plasma neurofilament light chain levels reflect caregiver burden and social cognition measures in familial frontotemporal lobar degeneration (FTLD)

58. Genome-wide structural variant analysis identifies risk loci for non-Alzheimer’s dementias

59. Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression

60. Longitudinal Measurements of Glucocerebrosidase activity in Parkinson’s patients

61. Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease

62. Genome‐wide transcriptome analysis identifies novel dysregulated genes implicated in Alzheimer's pathology

63. Leveraging genome-wide data to investigate differences between opioid use vs. opioid dependence in 41,176 individuals from the Psychiatric Genomics Consortium

64. Quality of life and caregiver burden in familial frontotemporal lobar degeneration: Analyses of symptomatic and asymptomatic individuals within the LEFFTDS cohort

65. Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study.

66. Genome‐wide association studies of the self‐rating of effects of ethanol (SRE)

67. Exceptionally low likelihood of Alzheimer's dementia in APOE2 homozygotes from a 5,000-person neuropathological study.

68. Clinical and volumetric changes with increasing functional impairment in familial frontotemporal lobar degeneration.

69. Individualized atrophy scores predict dementia onset in familial frontotemporal lobar degeneration.

70. The longitudinal evaluation of familial frontotemporal dementia subjects protocol: Framework and methodology

71. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.

72. Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIH-EXAMINER as a potential clinical trial endpoint.

73. Proteomic profiles for Alzheimer's disease and mild cognitive impairment among adults with Down syndrome spanning serum and plasma: An Alzheimer's Biomarker Consortium-Down Syndrome (ABC-DS) study.

74. Utility of the global CDR® plus NACC FTLD rating and development of scoring rules: Data from the ARTFL/LEFFTDS Consortium

75. Genetic screening of a large series of North American sporadic and familial frontotemporal dementia cases

76. Women can bear a bigger burden: ante- and post-mortem evidence for reserve in the face of tau

77. Nonlinear Z-score modeling for improved detection of cognitive abnormality.

78. Structures of α-synuclein filaments from human brains with Lewy pathology

79. Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease: a cross-sectional study

80. ERRATUM: Genome‐wide association study identifies loci associated with liability to alcohol and drug dependence that is associated with variability in reward‐related ventral striatum activity in African‐ and European‐Americans

81. Tracking white matter degeneration in asymptomatic and symptomatic MAPT mutation carriers

82. Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls

83. Persistent Changes in Stress‐Regulatory Genes in Pregnant Women or Children Exposed Prenatally to Alcohol

84. Genome‐wide association studies of alcohol dependence, DSM‐IV criterion count and individual criteria

85. Genome‐wide association study identifies loci associated with liability to alcohol and drug dependence that is associated with variability in reward‐related ventral striatum activity in African‐ and European‐Americans

86. P2‐314: THE MULTIDOMAIN IMPAIRMENT RATING (MIR) SCALE: INITIAL RELIABILITY DATA ON A MULTIDIMENSIONAL SCALE DESIGNED FOR FTLD SPECTRUM DISORDERS

87. Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI)

88. Genome-wide association study identifies 30 loci associated with bipolar disorder

89. Telomere Shortening in the Alzheimer’s Disease Neuroimaging Initiative Cohort

90. Meta‐Analysis of Genetic Influences on Initial Alcohol Sensitivity

91. The Parkinson's progression markers initiative (PPMI) - establishing a PD biomarker cohort.

92. A large-scale genome-wide association study meta-analysis of cannabis use disorder

93. New insights into the genetic etiology of Alzheimer’s disease and related dementias

94. Multi-trait genome-wide association study of opioid addiction: OPRM1 and beyond

95. Comprehensive cross-sectional and longitudinal analyses of plasma neurofilament light across FTD spectrum disorders

96. Detecting significant genotype-phenotype association rules in bipolar disorder: market research meets complex genetics.

97. Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort.

98. 18F-florbetapir Positron Emission Tomography–determined Cerebral &bgr;-Amyloid Deposition and Neurocognitive Performance after Cardiac Surgery

99. Identification of genetic risk factors in the Chinese population implicates a role of immune system in Alzheimer’s disease pathogenesis

100. Evaluation of laboratory tests for cirrhosis and for alcohol use, in the context of alcoholic cirrhosis.

Catalog

Books, media, physical & digital resources